Literature DB >> 27234579

Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients.

Chi-Fu Jeffrey Yang1, Nicholas R Mayne1, Hanghang Wang1, Ryan R Meyerhoff1, Sameer Hirji1, Betty C Tong1, Matthew Hartwig1, David Harpole1, Thomas A D'Amico1, Mark Berry2.   

Abstract

BACKGROUND: This study analyzes the impact of age on perioperative outcomes and long-term survival of patients undergoing surgery after induction chemotherapy for non-small cell lung cancer.
METHODS: Short- and long-term outcomes of patients with non-small cell lung cancer who were at least 70 years and received induction chemotherapy followed by major lung resection (lobectomy or pneumonectomy) from 1996 to 2012 were assessed using multivariable logistic regression, Kaplan-Meier, and Cox proportional hazard analysis. The outcomes of these elderly patients were compared with those of patients younger than 70 years who underwent the same treatment from 1996 to 2012.
RESULTS: Of the 317 patients who met the study criteria, 53 patients were at least 70 years. The median age was 74 years (range, 70 to 82 years) in the elderly group, and induction chemoradiation was used in 24 (45%) patients. Thirty-day mortality was similar between the younger (n = 12) and elderly (n = 3) patients (5% versus 6%; p = 0.52). There were no significant differences in the incidence of postoperative complications between younger and elderly patients (49% versus 57%; p = 0.30). Patients younger than 70 years had a median overall survival (30 months; 95% confidence interval [CI], 24 to 43) and a 5-year survival (39%; 95% CI, 33 to 45) that was not significantly different from patients at least 70 years (median overall survival, 30 months; 95% CI, 18 to 68; and 5-year overall survival, 36%; 95% CI, 21 to 51). However, there was a trend toward worse survival in the elderly group after multivariable adjustment (hazard ratio, 1.43; 95% CI, 0.97 to 2.12; p = 0.071).
CONCLUSIONS: Major lung resection after induction chemotherapy can be performed with acceptable short- and long-term results in appropriately selected patients at least 70 years, with outcomes that are comparable to those of younger patients.
Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27234579      PMCID: PMC5142525          DOI: 10.1016/j.athoracsur.2016.03.088

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  10 in total

1.  Prognostic models of thirty-day mortality and morbidity after major pulmonary resection.

Authors:  D H Harpole; M M DeCamp; J Daley; K Hur; C A Oprian; W G Henderson; S F Khuri
Journal:  J Thorac Cardiovasc Surg       Date:  1999-05       Impact factor: 5.209

2.  A retrospective analysis comparing patients 70 years or older to patients younger than 70 years with non-small-cell lung cancer treated with surgery at Indiana university: 1989-1999.

Authors:  Nasser Hanna; Jo Ann Brooks; Joanne Fyffe; Kenneth Kesler
Journal:  Clin Lung Cancer       Date:  2002-02       Impact factor: 4.785

3.  Survival and outcomes of surgical treatment of the elderly NSCLC in China: a retrospective matched cohort study.

Authors:  J Fan; X J Wang; G N Jiang; L Wang; X W Zu; X Zhou; W Gao; J A Ding
Journal:  Eur J Surg Oncol       Date:  2007-03-26       Impact factor: 4.424

4.  Long-term survival after non-small cell lung cancer surgery: development and validation of a prognostic model with a preoperative and postoperative mode.

Authors:  Ozcan Birim; A Pieter Kappetein; Marco Waleboer; John P A Puvimanasinghe; Marinus J C Eijkemans; Ewout W Steyerberg; Michel I M Versteegh; Ad J J C Bogers
Journal:  J Thorac Cardiovasc Surg       Date:  2006-09       Impact factor: 5.209

5.  Similar long-term survival of elderly patients with non-small cell lung cancer treated with lobectomy or wedge resection within the surveillance, epidemiology, and end results database.

Authors:  Carlos M Mery; Anastasia N Pappas; Raphael Bueno; Yolonda L Colson; Philip Linden; David J Sugarbaker; Michael T Jaklitsch
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

6.  Surgical management and outcomes of elderly patients with early stage non-small cell lung cancer: a nested case-control study.

Authors:  Caroline Rivera; Pierre-Emmanuel Falcoz; Alain Bernard; Pascal A Thomas; Marcel Dahan
Journal:  Chest       Date:  2011-03-24       Impact factor: 9.410

7.  Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.

Authors:  Taofeek K Owonikoko; Camille C Ragin; Chandra P Belani; Ana B Oton; William E Gooding; Emanuela Taioli; Suresh S Ramalingam
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

8.  Prospective assessment of 30-day operative morbidity for surgical resections in lung cancer.

Authors:  J Deslauriers; R J Ginsberg; S Piantadosi; B Fournier
Journal:  Chest       Date:  1994-12       Impact factor: 9.410

9.  Age does not worsen the efficacy nor tolerance to combined induction therapies in locally advanced non-small cell lung cancer.

Authors:  Diego Marquez-Medina; Antonio Martin-Marco; Amaia Ojanguren-Garranz
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

10.  Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.

Authors:  P Volpino; R Cangemi; E Fiori; B Cangemi; A De Cesare; N Corsi; T Di Cello; V Cangemi
Journal:  J Cardiovasc Surg (Torino)       Date:  2007-06       Impact factor: 1.888

  10 in total
  3 in total

1.  Thoracoscopic lobectomy after induction therapy-a paradigm shift?

Authors:  Sameer A Hirji; Asishana Osho; Stafford S Balderson; Thomas A D'Amico
Journal:  J Vis Surg       Date:  2017-12-21

Review 2.  [Progress of Neoadjuvant Therapy Combined with Surgery in Non-small Cell
Lung Cancer].

Authors:  Yaqi Wang; Xing Wang; Shi Yan; Yue Yang; Nan Wu
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2017-05-20

3.  Select octogenarians with stage IIIa non-small cell lung cancer can benefit from trimodality therapy.

Authors:  Andrew Tang; Andrew Feczko; Sudish C Murthy; Siva Raja; Alejandro Bribriesco; Dean Schraufnagel; Usman Ahmad; Daniel P Raymond; Monisha Sudarshan
Journal:  JTCVS Open       Date:  2022-02-23
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.